title: [Clinico-laboratory assessment of oframax (cefriaxone) in the treatment of infectious-inflammatory diseases].
abstract: OBJECTIVE
  To try efficacy and safety of ophramax (cephtriaxon) made in India ("Ranbaxy") in infectious-inflammatory diseases treated in a general hospital.
  
  
  METHODS
  Ophramax was given in a dose 1 to 4 g/day to 23 patients with pneumonia, chronic bronchitis, soft tissue infection, enterocolitis, etc. Therapeutic effect was examined with bacteriological identification of the infective agents, antibioticograms, agar diffusion test.
  
  
  RESULTS
  High sensitivity of pathogens to ophramax was observed in bronchopulmonary diseases (90.7%). In other infections sensitivity of the pathogens was 59.3%. Enterococci were the only highly resistant pathogens (40.5%). Ophramax remains in the body in sufficiently high concentrations for 24 hours. This attributes to good therapeutic effect.
  
  
  CONCLUSIONS
  Clinico-microbiological and pharmacokinetic findings show that ophramax can be used as a basic drug for treatment of different infectious-inflammatory diseases. Once-a-day regimen is a great advantage of ophramax.
authors.forename: V I
authors.initials: VI
authors.lastname: Sokolova
authors.forename: V A
authors.initials: VA
authors.lastname: Orlov
authors.forename: V A
authors.initials: VA
authors.lastname: Shenderovich
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001424:Bacterial Infections / Q000188:drug therapy*; D002443:Ceftriaxone / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D002511:Cephalosporins / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D016903:Drug Monitoring; D024881:Drug Resistance, Bacterial; D006801:Humans; D007249:Inflammation / Q000188:drug therapy*; D008875:Middle Aged
chemical_list: D002511:Cephalosporins; D002443:Ceftriaxone